Travere Therapeutics Inc. (tvtx 2.25 03/01/29)
13F holders, Q3 2025 (September 30)4holders +1
2new positions
1sold out
$1.13avg. 13F price*
At the end of Q3 2025, 4 institutions reported holding Travere Therapeutics Inc. (tvtx 2.25 03/01/29) in their 13F filings, up 1 from Q2 2025. 2 opened new positions and 1 sold out. The largest holders were Janus Henderson Group PLC ($7.2M), New York State Common Retirement Fund ($2.2M) and &partners ($18K).
- Company
- Travere Therapeutics Inc. (tvtx 2.25 03/01/29)
- CUSIP
- 89422GAA5
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $20K |
| Exits | 1 | $39.7M |
All 13F filers, Q2 2025 → Q3 2025: 18,000 shares bought and 47,431,000 shares sold, net −47,413,000 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Janus Henderson Group PLC | 0.00% | Reduce -44.2% | 6,356,000 | $7.2M |
| New York State Common Retirement Fund | 0.00% | Reduce -26.9% | 1,977,000 | $2.2M |
| &partners | 0.00% | New | 16,000 | $18K |
| Northwestern Mutual Wealth Management Co. | 0.00% | New | 2,000 | $2K |
"% of holder's portfolio" is TRAVERE THERAPEUTICS INC (TVTX 2.25 03/01/29)'s weight in each manager's 13F, not the share of Travere Therapeutics Inc. (tvtx 2.25 03/01/29) the manager owns.